Top Section/Ad
Top Section/Ad
Most recent
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
◆ Single digit premiums offered ◆ Reverse Yankees dominating euro supply ◆ Floaters proving popular with multi-tranche issuers
Pair enjoyed strong execution and tight pricing as US high grade credit remained resilient in the face of a sell-off in equity markets
More articles/Ad
More articles/Ad
More articles
-
Global equity markets were propelled to new all-time highs at the end of last year when various drug companies announced that they were close to releasing vaccines to combat the Covid-19 pandemic. However, with the vaccine roll-out slow, new mutant variants of the virus raging and governments striking a sombre tone, investors need to prepare for the fact that they may have bought in haste. -
The University of Manchester has signed a £250m revolving credit facility, following up a recent private placement covenant amendment with new debt to mitigate coronavirus pandemic risks.
-
Mainland-based Jinxin Fertility Group raised HK$1.27bn ($163.5m) in fresh equity on Monday after issuing a chunk of new shares.
-
Ethiopia announced on Monday its intention to restructure its debt under the G20’s Common Framework. However, the statement has been criticised for its lack of clarity. Market participants say the G20 must urgently confirm how creditor negotiations will take place.
-
Taiwan’s GaleMed Corp is tapping the loan market for a $70m-equivalent dual-currency deal for refinancing debt and dividend recapitalisation.
-
Biogroup’s debut in the high yield bond market has become one of the tightest ever triple-C rated issues, validating the former loan-only company’s decision to turn to public markets to add subordination to the refinancing of its capital structure.
